Analytical Data
-
Gene name
HLA-A*11:01&B2M&KRAS G12V(VVGAVGVGK) Monomer
- Application
-
Alternative Names
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAV53343.1 (G25-T305)&P61769
-
Expression Region
AAV53343.1 (G25-T305)&P61769 (I21-M119)&VVGAVGVGK
-
Molecular Weight
42-46 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*11:01, B2M, and KRAS G12V monomer recombinant proteins focuses on their roles in immune response and cancer biology. HLA-A*11:01 is a prominent human leukocyte antigen (HLA) allele that presents peptides to T cells, initiating immune responses. Its interaction with B2M (beta-2-microglobulin) is essential for the stability and surface expression of this HLA molecule. The KRAS G12V mutation, a common alteration found in various cancers, particularly pancreatic and colorectal tumors, leads to aberrant signaling pathways that promote cell proliferation and survival. The specific peptide VVGAVGVGK derived from the KRAS G12V mutation can be recognized by T cells in the context of HLA-A*11:01, making it a potential target for immunotherapy. Understanding the structural and functional characteristics of this recombinant protein complex is crucial for developing targeted treatments, as it allows researchers to investigate how the immune system can be harnessed to recognize and eliminate cancer cells expressing this mutant antigen. The insights gained from studying this protein complex could pave the way for innovative therapeutic strategies, including vaccine development and personalized cancer immunotherapy.
